Skip to main content

IBM and LION bioscience Alliance Paves the Way for Faster Drug Discovery

Combined IT and life sciences expertise to set new standards for data analysis and integration

ARMONK, NY, & HEIDELBERG, GERMANY - 28 Nov 2001: IBM and LION bioscience AG (Neuer Markt: LIO, WKN 504 350; Nasdaq: LEON) today announced a strategic alliance that promises sweeping changes in the way drug makers conduct research and develop new drug targets.

Through the far-reaching agreement, IBM and LION will work together to tackle what many researchers say is an overwhelming problem: Harnessing the avalanche of data pouring in from human genome studies so that it can be used for more effective and faster drug discovery and development.

The alliance merges industry-leading technologies for scientific data analysis, management and integration with a powerful information technology (IT) infrastructure and implementation services to offer a more comprehensive and coordinated approach to research and development. New solutions based on the combined technologies and services will make it easier for researchers to capture and utilize information from the widest range of data sources, and accelerate the development of new treatments for genetically-linked diseases.

The agreement is expected to set new standards for how enterprises analyze and manage diverse scientific and medical data, as well as significantly improve business management processes within the R&D community. Terms include:

"IBM's alliance with LION will benefit researchers around the world by creating a rock-solid IT foundation for advanced research and development," said Dr. Caroline Kovac, general manager, IBM Life Sciences. "The synergy between our technologies will put drug discovery on a faster track and give our mutual global customers unprecedented access to scientific data and advanced tools for knowledge management, data integration and collaboration."

A key provision of the agreement will enable DiscoveryLink data integration software to be connected to SRS, which provides access to more than 450 public and private databases, including GenBank, MEDLINE®, SwissProt, and others. Both complementary integration technologies make it possible to extract data from numerous sources with a single query. SRS and DiscoveryLink also apply a "federated data" approach, allowing data to remain in its original format and location, while queries are executed across those databases and results are returned in a single file.

"This strategic partnership couples IBM's unparalleled expertise in enterprise-wide IT-infrastructure and global marketing capabilities with LION's vast scientific expertise in developing enterprise-wide i-biology® solutions for the life sciences," said Dr. Friedrich von Bohlen, chief executive officer of LION bioscience. "Together, we will provide customers, as well as our internal drug discovery unit, with the ultimate IT-driven solution to improve performance of the entire R&D chain in the industry."

Contact(s) information

Theo Chisholm
IBM Media Relations
(914) 766-1180
theoc@us.ibm.com

Ernie Knewitz
Noonan/Russo Communications, Inc.
(212) 696-4455, x204
e.knewitz@noonanrusso.com

Dr. Andrea Kreisselmeier
LION bioscience AG
(49) 6221-4038-265
andrea.kreisselmeier@lionbioscience.com

Related XML feeds
Topics XML feeds
Research
Chemistry, computer science, electrical engineering, materials and mathematical sciences, physics and services science
Software
Information Management, Lotus, Tivoli, Rational, WebSphere, Open standards, open source